FILIPPE CAMAROTTO MOTA

Índice h a partir de 2011
4
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Assunto: Surgery ×

Resultados de Busca

Agora exibindo 1 - 10 de 12
  • article 1 Citação(ões) na Scopus
    Exclusions May Be Dismissed if the Ileum Is Early and Potently Stimulated
    (2021) SANTORO, Sergio; AQUINO, Caio Gustavo Gaspar; MOTA, Filippe Camarotto
  • article 4 Citação(ões) na Scopus
    Early glycemic control and incretin improvement after gastric bypass: the role of oral and gastrostomy route
    (2019) FERNANDES, Gustavo; SANTO, Marco Aurelio; CRESPO, Andrea de Fatima Crispino Bastos; BIANCARDI, Gabriel Barbosa; MOTA, Filippe Camarotto; ANTONANGELO, Leila; CLEVA, Roberto de
    Background: Patients with obesity have a suppressed incretin effect and a consequent imbalance of glycemic homeostasis. Several studies have shown improved type 2 diabetes after Roux-en-Y gastric bypass (RYGB). The mechanisms of early action are linked to caloric restriction, improvement of insulin resistance, pancreatic beta cell function, and the incretin effect of glycogen-like protein 1 and gastric inhibitory polypeptide, but reported data are conflicting. Objective: The objective of this study was to evaluate glycemic metabolism, including the oral glucose tolerance test and enterohormonal profile in the early postoperative period in severely obese patients who underwent RYGB with gastrostomy, comparing the preoperative supply of a standard bolus of nutrient against the postoperative administration through an oral and a gastrostomy route. Setting: Clinics Hospital of University of Sao Paulo, Brazil. Methods: Eleven patients with obesity and diabetes underwent RYGB with a gastrostomy performed in the excluded gastric remnant. Patients were given preoperative assessments of glycemic and enterohormone profiles and an oral glucose tolerance test; these were compared with early postoperative assessments after oral and gastrostomy route administrations. Results: The mean preoperative body mass index of the group was 44.1 +/- 6.6 kg/m(2), mean fasting blood glucose of 194.5 +/- 62.4 mg/dL, and glycated hemoglobin 8.7 +/- 1.6%. In 77.7% of the patients, there was normalization of the glycemic curve in the early postoperative period as evaluated by the oral glucose tolerance test. Significant decreases in glycemia, insulinemia, and homeostatic model assessment-insulin resistance were also observed, regardless of the route of administration. There was significant increase in glycogen-like protein 1 by the postoperative oral route and reduction of gastric inhibitory polypeptide in both routes. Ghrelin did not change. Conclusion: Glycemia and peripheral insulin resistance reductions were observed in early postoperative RYGB, independent of the oral or gastrostomy route. Incretin improvement, mediated by glycogen-like protein 1 increased was observed only in the postoperative oral route, while GIP reduced for both routes.
  • conferenceObject
    ANALYSIS OF LIVER FUNCTION IN THE OBESE PATIENT AND ITS CORRELATION WITH METABOLIC COMORBIDITIES NASH and bariatric surgery
    (2019) SILVA, M. B. D. B. E.; MESQUITA, G. H. A. D.; MOTA, F. C.; KAWAMOTO, F. M.; DANTAS, A. C. B.; MARSON, A. G.; MATSUDA, M.; ANDRAUS, W.; SANTO, M. A.
  • conferenceObject
    RESTING METABOLIC RATE AND WEIGHT LOSS AFTER BARIATRIC SURGERY Integrated Health/Multidisciplinary care
    (2017) MOTA, F.; CLEVA, R.; GADDUCCI, A.; CARDIA, L.; GREVE, J.; SILVA, P. R.; SANTO, M. A.
  • conferenceObject
    BODY COMPOSITION AND RESTING METABOLIC RATE IN WEIGHT LOSS AFTER BARIATRIC SURGERY
    (2016) SANTO, M. A.; MOTA, F. C.; V, A. Gadducci; SANTAREM, G. C.; SILVA, P. R.; GREVE, J.; CLEVA, R.
  • conferenceObject
    LIVER FUNCTION IMPROVEMENT AFTER BARIATRIC SURGERY: USING THE INDOCYANINE GREEN TEST IN THE FOLLOW-UP OF OBESE PATIENTS NASH and bariatric surgery
    (2019) SILVA, M. B. D. B. E.; MESQUITA, G. H. A. D.; DANTAS, A. C. B.; MOTA, F. C.; KAWAMOTO, F. M.; PAJECKI, D.; RICCIOPPO, D.; CLEVA, R. D.; ANDRAUS, W.; SANTO, M. A.; CECCONELLO, I.
  • conferenceObject
    SMALL BOWEL OBSTRUCTION CAUSED BY GASTRIC BAND MIGRATION TO PROXIMAL JEJUNUM Adjustable gastric banding
    (2019) KAWAMOTO, F. M.; SILVA, M. B. D. B. E.; STOLZEMBURG, L. C. P.; MOTA, F. C.; SANTO, M. A.
  • conferenceObject
    MANAGEMENT OF GASTROINTESTINAL LEAKS AFTER BARIATRIC SURGERY
    (2016) SANTO, M. A.; MOTA, F. C.; PAJECKI, D.; RICCIOPPO, D.; KAWAMOTO, F.; JOAQUIM, H.; BATISTA, A. C.; CLEVA, R.
  • article 26 Citação(ões) na Scopus
    Neoadjuvant therapy or upfront surgery? A systematic review and meta-analysis of T2N0 esophageal cancer treatment options
    (2018) MOTA, F. C.; CECCONELLO, I.; TAKEDA, F. R.; TUSTUMI, F.; SALLUM, R. A. A.; BERNARDO, W. M.
    Background: Esophageal carcinoma usually shows poor long-term survival rates, even when esophagectomy, the standard curative treatment is performed. As a result, there has been increasing interest in the neoadjuvant therapy, which could potentially downstage cancer, eliminate micrometastasis and ergo increase resectability and curative (R0) resection. Currently, for the earliest stage esophageal cancers, most guidelines point out to the role of endoscopic treatment, and for T1bN0 upfront surgery. For locally advanced cases, several studies have demonstrated the benefits of neoadjuvant therapy to increase resectability. For clinical stage T2N0 esophageal cancer, there is no consensus as to the optimal treatment strategy. Methods: A systematic review and meta-analysis was performed to compare neoadjuvant therapy with surgery alone on clinical stage T2N0 esophageal cancer patients, concerning overall survival, recurrence, post-operative mortality, anastomotic leak, and R0 resection rate. Results: For overall survival at the mean follow-up point, the neoadjuvant therapy was not associated to a higher probability of survival than upfront surgery in cT2N0 patients (risk difference: 0.00; 95% CI: -0.09, 0.09). There was no difference between neoadjuvant therapy and primary surgery concerning recurrence (risk difference: 0.21; 95% CI: -0.03, 0.45); perioperative mortality (risk difference: 0.00; 95% CI: -0.02, 0.01); and risk for anastomotic leak (risk difference: -0.08; 95% CI: -0.21, 0.05). Pooled data showed that neoadjuvant therapy was associated to a higher risk for positive margins after resection (risk difference: 0.04; 95% CI: 0.02, 0.06). Conclusions: This review showed that neoadjuvant therapy is not associated to better results than surgery alone, for the management of clinical stage T2N0 esophageal cancer patients, concerning overall survival, recurrence rate, perioperative mortality, anastomotic leak, and seems to be associated to a higher risk for resection with positive margins.
  • conferenceObject
    LIVER FUNCTION EVALUATION IN OBESE PATIENTS: THE INDOCYANINE GREEN (ICG) TEST VERSUS THE AST TO PLATELET RATIO INDEX (APRI) NASH and bariatric surgery
    (2019) SILVA, M. B. D. B. E.; MESQUITA, G. H. A. D.; DANTAS, A. C. B.; MOTA, F. C.; KAWAMOTO, F. M.; JOAQUIM, H. D. G.; PINTO JR., P. E.; PAJECKI, D.; ANDRAUS, W.; SANTO, M. A.